| Title |
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
|
|---|---|
| Published in |
Investigational New Drugs, July 2013
|
| DOI | 10.1007/s10637-013-9999-7 |
| Pubmed ID | |
| Authors |
William R. Schelman, Tabraiz A. Mohammed, Anne M. Traynor, Jill M. Kolesar, Rebecca M. Marnocha, Jens Eickhoff, Michael Keppen, Dona B. Alberti, George Wilding, Naoko Takebe, Glenn Liu |
| Abstract |
A phase I, dose-escalation study of AT-101 with cisplatin and etoposide was conducted to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), safety and pharmacokinetics in patients with advanced solid tumors, with an expanded cohort in patients with extensive-stage small cell lung cancer (ES-SCLC) to assess preliminary activity. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 26% |
| Student > Bachelor | 6 | 18% |
| Researcher | 5 | 15% |
| Other | 3 | 9% |
| Student > Doctoral Student | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 4 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 26% |
| Biochemistry, Genetics and Molecular Biology | 6 | 18% |
| Nursing and Health Professions | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Engineering | 2 | 6% |
| Other | 5 | 15% |
| Unknown | 6 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 July 2013.
All research outputs
#18,341,711
of 22,714,025 outputs
Outputs from Investigational New Drugs
#873
of 1,165 outputs
Outputs of similar age
#128,818
of 172,131 outputs
Outputs of similar age from Investigational New Drugs
#5
of 7 outputs
Altmetric has tracked 22,714,025 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,165 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,131 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.